GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and dexamethasone (BorDex ...

The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard treatment. A phase 3 study in newly diagnosed transplant-ineligible multiple ...

GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of the treatment returning to market after the drugmaker announced positive trial results.

(RTTNews) - Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection ...

Blenrep helped patients whose myeloma has relapsed to live longer when combined with cancer therapy BorDex. The British drugmaker said Thursday the results of the late-stage trial are ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.